Back to ACADView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
1 competitor in Rett Syndrome
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/20/2026
Daybu
Daybu is indicated for the treatment of Rett syndrome in adults and paediatric patients 2 years of age and older.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Pimavanserin 34 mgPhase 3
Dementia-related Psychosis
CarbetocinPhase 3
Hyperphagia in Prader-Willi Syndrome
pimavanserin tartratePhase 3
Parkinson's Disease Psychosis
Pimavanserin tartrate (ACP-103)Phase 3
Parkinson's Disease Psychosis
PimavanserinPhase 3
Agitation and Aggression in Alzheimer's Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts